Subscribe To
The swiss national bank will be publishing a report on monetary policy on wednesday
The Swiss National Bank (SNB)'s Quarterly Bulletin for Q2 2023 will be released at 1300 GMT, which is 0900 US Eastern time. The Bulletin typically inc...
June 28, 2023, 2:26 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Oncolytics biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial
The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selecte...
June 22, 2023, 1:12 pm
European economic news preview: bank of england monetary policy decision due
The monetary policy announcements from the Bank of England and the Swiss National Bank are the major events due on Thursday. At 2.45 am ET, France’s...
June 22, 2023, 5:17 am
Biocardia announces fda completes review of proposed adaptive statistical analysis design for ongoing cardiamp cell therapy in heart failure pivotal study
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the ...
June 20, 2023, 9:14 pm
Vera therapeutics shares surge on positive igan trial results
Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicep...
June 20, 2023, 3:56 pm
Lilly's (lly) migraine drug fails vis-a-vis pfizer's nurtec odt
Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistic...
June 19, 2023, 12:29 pm
Aldeyra's stellar allergic conjunctivitis results to raise reproxalap monetization value
Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease ...
June 16, 2023, 10:55 am
Abbvie's (abbv) skyrizi meets ulcerative colitis study goals
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remissi...
June 16, 2023, 9:20 am
Aldeyra therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic c...
June 15, 2023, 10:49 am
European economic news preview: italy industrial production data due
Industrial production from Italy is the only major statistical report due on Friday, headlining a light...
June 9, 2023, 5:40 am
3 dividend-paying large-cap stocks to buy in june
While going the route of dividend-paying large-cap stocks might not lead to gargantuan returns, you're likely to improve your odds of success. To use ...
June 8, 2023, 6:50 pm
Novocure: misunderstood lung cancer data creates enormous buy opportunity
NovoCure Limited's primary endpoint of phase 3 LUNAR study, using TTFields plus standard therapies for 2nd line metastatic NSCLC patients, was met wit...
June 6, 2023, 5:49 pm
Novocure's lung cancer device extends survival in late-stage study
Novocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically ...
June 6, 2023, 8:38 am
French industrial production recovers in april
France’s industrial production rebounded in April with the sharp recovery in petroleum output, the statistic...
June 2, 2023, 8:10 am